SCHEMBL8309353

SCHEMBL8309353

COCCN(CCN)CCOC

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.36
LCK P06239 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CTH P32929 1/20 0.31
CA2 P00918 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27224865 0.97 PIK3CD (0.34) PIK3CDLCKMEN1KMT2ACTH
SCHEMBL12131662 0.91 LCK (0.34) PIK3CDLCKMEN1KMT2A
SCHEMBL27579643 0.89 LCK (0.34) PIK3CDLCK
SCHEMBL7369255 0.87 MEN1 (0.34) PIK3CDMEN1KMT2A
SCHEMBL15739629 0.85 BLM (0.35) LCKCA2
SCHEMBL1292539 0.85 PIK3CD (0.43) PIK3CDMEN1KMT2ACTHCA2
SCHEMBL6417812 0.84 CHRM2 (0.33) PIK3CDLCKMEN1KMT2A
SCHEMBL8306690 0.84 LCK (0.41) LCK
SCHEMBL11793063 0.82 PIK3CD (0.42) PIK3CDMEN1KMT2ACTHCA2
SCHEMBL15745725 0.82 PIK3CD (0.42) PIK3CDMEN1KMT2ACTHCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 WO disclosed
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 EP disclosed
WO-2023071601-A1 DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 天津市昕晨投资发展有限公司 2023-05-04 WO disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 WO disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 WO disclosed
US-10364245-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2019-07-30 US disclosed
US-20180354945-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-12-13 US disclosed
US-20110243892-A1 Y-SHAPE BRANCHED HYDROPHILIC POLYMER DERIVATIVES, THEIR PREPARATION METHODS, CONJUGATES OF THE DERIVATIVES AND DRUG MOLECULES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE CONJUGATES JI SHISHAN 2011-10-06 US disclosed
US-8003089-B2 such as triethanolamine with 2 hydroxyethyl groups derivatized with polyethylene glycol, and the amine group conjugated to drugs such as antitumor agent interferon BEIJING JIANKAI TECHNOLOGY CO., LTD. (CN) 2011-08-23 US disclosed
EP-0790986-B1 ANILINE DERIVATIVES ZENECA LTD (GB) 1999-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354945-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K6 PIK3CD 773/4885LCK 471/4885MEN1 4752/4885
US-10364245-B2 Kinase inhibitors MAPK1, MAP3K1, MAP3K6 PIK3CD 773/4885LCK 471/4885MEN1 4752/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS PIK3CD 516/4885LCK 1456/4885MEN1 798/4885
US-20110243892-A1 Y-SHAPE BRANCHED HYDROPHILIC POLYMER DERIVATIVES, THEIR PREPARATION METHODS, CONJUGATES OF THE DERIVATIVES AND DRUG MOLECULES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE CONJUGATES EGFR, NPY5R, NPY4R PIK3CD 501/4885LCK 358/4885MEN1 2396/4885
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 PIK3CD 92/4885LCK 120/4885MEN1 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.